|
|
||||||||||
|
J Am Coll Cardiol, 1998; 32:140-146 © 1998 by the American College of Cardiology Foundation |






a Legacy Good Samaritan Hospital, Portland Cardiovascular Institute, Portland, Oregon, USA
* Department of Medicine, Brigham and Womens Hospital and Harvard Medical School, Boston, Massachusetts, USA
Baylor University Medical Center, Dallas, Texas, USA
University of South Florida, Tampa, Florida, USA
University of Alabama, Birmingham, Alabama, USA
|| University of Washington Medical Center, Seattle, Washington, USA
# University of Florida Medical Center, Gainesville, Florida, USA
** University of Texas School of Public Health, Houston, Texas, USA

Montreal Heart Institute, Montreal, Quebec, Canada
Manuscript received November 26, 1997; revised manuscript received March 17, 1998, accepted April 9, 1998.
Address for correspondence: Dr. Frank Sacks, Nutrition Department, Harvard School of Public Health, 665 Huntington Avenue, Boston, Massachusetts 02115
fsacks{at}hsph.harvard.edu
Objectives. We sought to determine the effect of pravastatin on recurrent cardiovascular events in women with average cholesterol levels after myocardial infarction (MI).
Background. Little information is available on the effectiveness of lipid lowering in secondary prevention of coronary heart disease (CHD) in women; in particular, those with CHD and average cholesterol levels.
Methods. In the Cholesterol and Recurrent Events (CARE) trial, 576 postmenopausal women, between 3 and 20 months after MI, with a total cholesterol level <240 mg/dl and a low density lipoprotein cholesterol level 115 to 174 mg/dl, were randomized to receive pravastatin 40 mg/day or matching placebo for a median follow-up period of 5 years. The main outcome measures were combined coronary events (coronary death, nonfatal MI, percutaneous transluminal coronary angioplasty [PTCA] or coronary artery bypass graft surgery [CABG]), the primary trial end point (coronary death or nonfatal MI) and stroke.
Results. Women treated with pravastatin had a risk reduction of 43% for the primary end point (p = 0.035), 46% for combined coronary events (p = 0.001), 48% for PTCA (p = 0.025), 40% for CABG (p = 0.14) and 56% for stroke (p = 0.07). The 3,583 men in the CARE trial also showed a reduction in risk, but the magnitude tended to be less. Pravastatin improved plasma lipids similarly in men and women. There were no differences in risk of coronary events in the placebo group between men and women. Minor differences between men and women were present in baseline characteristics and treatment for MI, in general, conferring a higher risk status and a lower incidence of CABG in the women.
Conclusions. Pravastatin led to significant early reduction of a wide range of cardiovascular events in post-MI women with average cholesterol levels.
| ||||||||||||||||||||
This article has been cited by other articles:
![]() |
N K Wenger, S J Lewis, F K Welty, D M Herrington, V Bittner, and on behalf of the TNT Steering Committee and Invest Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study Heart, April 1, 2008; 94(4): 434 - 439. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Pilote, K. Dasgupta, V. Guru, K. H. Humphries, J. McGrath, C. Norris, D. Rabi, J. Tremblay, A. Alamian, T. Barnett, et al. A comprehensive view of sex-specific issues related to cardiovascular disease Can. Med. Assoc. J., March 13, 2007; 176(6): S1 - S44. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. S Houslay, J. Sarma, and N. G Uren The effect of intensive lipid lowering on coronary atheroma and clinical outcome Heart, February 1, 2007; 93(2): 149 - 151. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Karp, S.-F. Chen, and L. Pilote Sex differences in the effectiveness of statins after myocardial infarction Can. Med. Assoc. J., January 30, 2007; 176(3): 333 - 338. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. Bushnell, J. Griffin, L. K. Newby, L. B. Goldstein, K. W. Mahaffey, C. A. Graffagnino, R. A. Harrington, H. D. White, R. J. Simes, R. M. Califf, et al. Statin Use and Sex-Specific Stroke Outcomes in Patients With Vascular Disease Stroke, June 1, 2006; 37(6): 1427 - 1431. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Zhou, E. Rahme, M. Abrahamowicz, J. V. Tu, M. J. Eisenberg, K. Humphries, P. C. Austin, and L. Pilote Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect Can. Med. Assoc. J., April 26, 2005; 172(9): 1187 - 1194. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Meagher Addressing Cardiovascular Disease in Women: Focus on Dyslipidemia J Am Board Fam Med, November 1, 2004; 17(6): 424 - 437. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. E. Walsh and M. Pignone Drug Treatment of Hyperlipidemia in Women JAMA, May 12, 2004; 291(18): 2243 - 2252. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Yokoyama, Y. Inoue, T. Moritan, K. Ohtomo, and R. Nagai Impaired myocardial vasodilatation during hyperaemic stress is improved by simvastatin but not by pravastatin in patients with hypercholesterolaemia Eur. Heart J., April 2, 2004; 25(8): 671 - 679. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Oparil Improving outcomes for women after coronary artery bypass grafting: A case for prevention J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 1704 - 1706. [Full Text] [PDF] |
||||
![]() |
R. A. Kreisberg and A. Oberman Medical Management of Hyperlipidemia/Dyslipidemia J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2445 - 2461. [Full Text] [PDF] |
||||
![]() |
L. H. Kuller Hormone Replacement Therapy and Risk of Cardiovascular Disease: Implications of the Results of the Women's Health Initiative Arterioscler. Thromb. Vasc. Biol., January 1, 2003; 23(1): 11 - 16. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Stangl, G. Baumann, and K. Stangl Coronary atherogenic risk factors in women Eur. Heart J., November 2, 2002; 23(22): 1738 - 1752. [Full Text] [PDF] |
||||
![]() |
J.E. Deanfield The management of special patient populations Eur. Heart J. Suppl., September 1, 2002; 4(suppl_F): F19 - F23. [Abstract] [PDF] |
||||
![]() |
W. S. Aronow Guest Editorial: Should Hypercholesterolemia in Older Persons Be Treated to Reduce Cardiovascular Events? J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2002; 57(7): M411 - 413. [Full Text] |
||||
![]() |
D. M. Herrington, E. Vittinghoff, F. Lin, J. Fong, F. Harris, D. Hunninghake, V. Bittner, H. G. Schrott, R. S. Blumenthal, R. Levy, et al. Statin Therapy, Cardiovascular Events, and Total Mortality in the Heart and Estrogen/Progestin Replacement Study (HERS) Circulation, June 25, 2002; 105(25): 2962 - 2967. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E Roeters van Lennep, H.T. Westerveld, D.W. Erkelens, and E. E van der Wall Risk factors for coronary heart disease: implications of gender Cardiovasc Res, February 15, 2002; 53(3): 538 - 549. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Kreisberg and A. Oberman Lipids and Atherosclerosis: Lessons Learned from Randomized Controlled Trials of Lipid Lowering and Other Relevant Studies J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 423 - 437. [Full Text] [PDF] |
||||
![]() |
J. B. Braunstein, A. Cheng, G. Cohn, M. Aggarwal, C. M. Nass, and R. S. Blumenthal Lipid Disorders : Justification of Methods and Goals of Treatment Chest, September 1, 2001; 120(3): 979 - 988. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. S. Aronow Treatment of Older Persons With Hypercholesterolemia With and Without Cardiovascular Disease J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2001; 56(3): 138M - 145. [Abstract] [Full Text] |
||||
![]() |
F. K. Welty Cardiovascular Disease and Dyslipidemia in Women Arch Intern Med, February 26, 2001; 161(4): 514 - 522. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.G. Isles and J.R. Paterson Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy QJM, September 1, 2000; 93(9): 567 - 574. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Rajaratnam, H. Gylling, and T. A. Miettinen Independent association of serum squalene and noncholesterol sterols with coronary artery disease in postmenopausal women J. Am. Coll. Cardiol., April 1, 2000; 35(5): 1185 - 1191. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Miller, R. Byington, D. Hunninghake, B. Pitt, C. D. Furberg, and for the Prospective Randomized Evaluation of the V Sex Bias and Underutilization of Lipid-Lowering Therapy in Patients With Coronary Artery Disease at Academic Medical Centers in the United States and Canada Arch Intern Med, February 14, 2000; 160(3): 343 - 347. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Stewart, A. G. Jardine, and J. D. Briggs Ischaemic heart disease following renal transplantation Nephrol. Dial. Transplant., February 1, 2000; 15(2): 269 - 277. [Full Text] [PDF] |
||||
![]() |
J. C. LaRosa, J. He, and S. Vupputuri Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials JAMA, December 22, 1999; 282(24): 2340 - 2346. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Ansell, K. E. Watson, and A. M. Fogelman An Evidence-Based Assessment of the NCEP Adult Treatment Panel II Guidelines JAMA, December 1, 1999; 282(21): 2051 - 2057. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. H. Beck and S. P. Kumar Update in Preventive Medicine Ann Intern Med, November 2, 1999; 131(9): 681 - 687. [Full Text] [PDF] |
||||
![]() |
C. X. Pan, J. Boal, for the Geriatrics Journal Club, E. Banks, V. Beral, P. J. L. Ong, M. B. Sorensen, C. S. Hayward, C. M. Webb, P. Collins, et al. Hormone Replacement Therapy for Secondary Prevention of Coronary Heart Disease JAMA, March 3, 1999; 281(9): 794 - 797. [Full Text] [PDF] |
||||
![]() |
Pravastatin Effective in Women After MI Journal Watch Women's Health, September 1, 1998; 1998(901): 1 - 1. [Full Text] |
||||
![]() |
Lowering Lipids Works in Women Too Journal Watch Cardiology, August 14, 1998; 1998(814): 1 - 1. [Full Text] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |